![]() Clinical cutaneous manifestations of the patients were erythematous rash, chickenpox‐like vesicles, and widespread urticaria. 2 Recalcati et al did a study on 88 patients, and 18 of them developed cutaneous manifestations. The first scientific report about the relationship between COVID‐19 and rashes was done in China and was about skin involvement. E, F Figures showing a maculopapular mild itchy rash on her face and extremities after HCQ treatment in a 17‐year‐old teenager C, D Figures showing a maculopapular and itchy rash on her face and shoulder in a 11‐year‐old child. ![]() All of the other viral markers were normal for these three patients.Ī, B Figures showing an erythematous skin rash and had a similar appearance to the rash of roseola on his face and trunk in an 8‐month‐old child. Three patients had normal coagulation patterns. We did not detect any correlation between the exacerbation of the rash and the disease's severity. Generally, all of the patients' rashes started on their faces and continued on the extremities and ended on the trunk. Therefore, we concluded that her skin rash occurred due to the usage of HCQ and her rash after the termination of HCQ treatment. During the fourth day of hospitalization of the oldest, a 17‐year‐old patient, the patient developed a maculopapular mild itchy rash on the third day of HCQ treatment (Figure 1E,F). The second patient, an 11‐year‐old girl, had a maculopapular and itchy rash at the time of admission to the hospital, which lasted for 5 days (Figure 1C,D). Her rash and fever lasted for 2 days, and both clinical conditions disappeared concomitantly (Figure 1A,B). The youngest patient, an 8‐month‐old girl, had an erythematous skin rash and had a similar appearance to the rash of roseola. Cutaneous manifestations were maculopapular rashes (two patients) and erythematosus eruptions (one patient). Two patients (10%) developed cutaneous involvement at the onset, one patient (5%) developed cutaneous involvement after HCQ treatment during the hospitalization. Three patients (15%) developed cutaneous manifestations. The exact diagnosis of each patient was confirmed by nasopharyngeal and oropharyngeal swab PCR. In all of 20 pediatric patients, nine of them received HCQ treatment. ![]() Twenty pediatric patients with COVID‐19 were hospitalized at the hospital from 20 March to 25 April. We have tried to analyze the appearance of the rash in pediatric patients with and/or without using hydroxychloroquine (HCQ) treatment for the treatment of COVID‐19 who have been hospitalized at our hospital. 1 Many different clinical manifestations of COVID‐19 have been described in the literature though there have not been any reported cases in the literature about skin manifestations related to COVID‐19 in pediatric patients. Coronavirus disease (COVID‐19) is spreading across the world.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |